Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of T3P-Y058-739 in advanced solid tumours
2023-504199-19-00Phase 2Authorised
- Sponsor
- T3 Pharmaceuticals
- Start
- Jun 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of T3P-Y058-739 in Nonhematologic neoplasms, sponsored by T3 Pharmaceuticals. Planned start Jun 2024; status: authorised.
02
Drugs
T3P-Y058-739
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-504199-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504199-19-00.